On December 10, Gelonghui reported that DaShenLin Pharmaceutical Group (603233.SH) announced plans to adjust the investment scale and project completion of the "Nam Cheong DaShenLin Industrial Base Project (Phase One)". The project plans to use raised funds of 128.1401 million yuan, with actual raised fund usage of 67.262 million yuan, and the remaining raised funds (as of November 28, 2024, actual balance of the raised funds account is 65.8996 million yuan, including interest income, etc.) will be permanently added to working capital.
大参林(603233.SH)：拟调整募投项目“南昌大参林产业基地项目(一期)”的投资规模及结项
DaShenLin Pharmaceutical Group (603233.SH): Plans to adjust the investment scale of the "Nam Cheong DaShenLin Industrial Base Project (Phase I)" and its completion.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated